NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated.

The immuno-oncology company expects the round to fund a Phase I/II trial of adoptive cellular therapy AIM ACT that is due to begin this year and will enroll patients with acute myelogenous leukemia (AML) and/or myelodysplastic syndromes who have relapsed after an allogeneic hematopoietic stem cell (HSC) transplant...